Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan 19;27(4):231-234.
doi: 10.4103/meajo.MEAJO_216_19. eCollection 2020 Oct-Dec.

Nodular Posterior Scleritis Masquerading as a Subretinal Mass

Affiliations
Case Reports

Nodular Posterior Scleritis Masquerading as a Subretinal Mass

Naseer Ally et al. Middle East Afr J Ophthalmol. .

Abstract

This is the case report of a 50-year-old female with no systemic comorbidities who presented to the eye clinic with a 1-month history of right-sided eye pain and visual loss. Examination revealed no signs of inflammation in the right eye, with no proptosis or conjunctival injection. A relative afferent pupillary defect was present with no inflammatory cells in the vitreous. On fundoscopy, there was a swollen disc, a large superior creamy white subretinal mass associated with a shallow overlying retinal detachment. B-scan ultrasonography confirmed the presence of a subretinal mass. Hematological investigations revealed an elevated erythrocyte sedimentation rate. Infective and autoimmune markers were negative. A diagnosis was made of nodular posterior scleritis and the patient was treated with intravenous corticosteroids initially, and subsequently switched to oral corticosteroids. There was complete resolution of the mass with optic atrophy as a result. Posterior nodular scleritis is an extremely rare potentially vision-threatening ocular condition that requires multimodal investigations to diagnose and treat appropriately.

Keywords: Nodular scleritis; posterior scleritis; subretinal mass.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
(a and b) Fundus pictures of subretinal mass on admission. (c) After 3 days of intravenous steroid treatment. (d) After 1 month of steroid treatment (initially intravenous and subsequently oral treatment)
Figure 2
Figure 2
B-scan ultrasonography showing the hyperechoic subretinal mass
Figure 3
Figure 3
Macula optical coherence tomography of the right eye pre-treatment with systemic steroids
Figure 4
Figure 4
Macula optical coherence tomography of the right eye post-treatment with systemic steroids

Similar articles

References

    1. McCluskey PJ, Watson PG, Lightman S, Haybittle J, Restori M, Branley M. Posterior scleritis: Clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 1999;106:2380–6. - PubMed
    1. Agrawal R, Lavric A, Restori M, Pavesio C, Sagoo MS. Nodular posterior scleritis: Clinico-sonographic characteristics and proposed diagnostic criteria. Retina. 2016;36:392–401. - PubMed
    1. Tanaka R, Kaburaki T, Ohtomo K, Takamoto M, Komae K, Numaga J, et al. Clinical characteristics and ocular complications of patients with scleritis in Japanese. Jpn J Ophthalmol. 2018;62:517–24. - PubMed
    1. Shukla D, Kim R. Giant nodular posterior scleritis simulating choroidal melanoma. Indian J Ophthalmol. 2006;54:120–2. - PubMed
    1. Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994;101:389–96. - PubMed

Publication types

MeSH terms